Search our Database of Scientific Publications and Authors

I’m looking for a

    1488 results match your criteria Cardiovascular Diabetology[Journal]

    1 OF 30

    Non-culprit plaque characteristics in acute coronary syndrome patients with raised hemoglobinA1c: an intravascular optical coherence tomography study.
    Cardiovasc Diabetol 2018 Jun 15;17(1):90. Epub 2018 Jun 15.
    Department of Cardiology, The 2nd Affiliated Hospital of Harbin Medical University, The Key Laboratory of Myocardial Ischemia, Chinese Ministry of Education, Harbin, China.
    Background: Raised hemoglobinA1c (HbA1c) is an indicator of pre-diabetes, which is associated with increased risk of coronary artery disease. However, the detailed morphological characteristics of non-culprit plaques in acute coronary syndrome (ACS) patients remain largely unknown.

    Methods: A total of 305 non-culprit plaques from 216 ACS patients were analyzed by intravascular optical coherence tomography. Read More

    Inhibition of calcium/calmodulin-dependent kinase II restores contraction and relaxation in isolated cardiac muscle from type 2 diabetic rats.
    Cardiovasc Diabetol 2018 Jun 14;17(1):89. Epub 2018 Jun 14.
    Otago School of Medical Sciences, Department of Physiology and HeartOtago, University of Otago, 270 Great King Street, Dunedin, 9016, New Zealand.
    Background: Calcium/calmodulin-dependent kinase II-delta (CaMKIIδ) activity is enhanced during hyperglycemia and has been shown to alter intracellular calcium handling in cardiomyocytes, ultimately leading to reduced cardiac performance. However, the effects of CaMKIIδ on cardiac contractility during type 2 diabetes are undefined.

    Methods: We examined the expression and activation of CaMKIIδ in right atrial appendages from non-diabetic and type 2 diabetic patients (n = 7 patients per group) with preserved ejection fraction, and also in right ventricular tissue from Zucker Diabetic Fatty rats (ZDF) (n = 5-10 animals per group) during early diabetic cardiac dysfunction, using immunoblot. Read More

    Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study.
    Cardiovasc Diabetol 2018 Jun 12;17(1):86. Epub 2018 Jun 12.
    Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Toho University Graduate School of Medicine, 6-11-1 Omori-Nishi, Ota-ku, Tokyo, 143-8541, Japan.
    Background: Recent studies reported that sodium glucose cotransporter 2 (SGLT2) inhibitors reduced the cardiovascular morbidity and mortality in patients with type 2 diabetes mellitus (T2DM) compared to placebo in contrast to no reduction with dipeptidyl peptidase 4 (DPP4) inhibitors. However, there are no comparative studies on the effects of SGLT2 inhibitors and DPP4 inhibitors on HbA1c, body weight and hypoglycemia as risk factors of cardiovascular diseases. The aim of the present ongoing study is to compare the effects of dapagliflozin, a SGLT2 inhibitor, with those of sitagliptin, a DPP4 inhibitor, on cardiovascular risk factors in T2DM patients with inadequate glycemic control. Read More

    Association between abdominal adiposity and subclinical measures of left-ventricular remodeling in diabetics, prediabetics and normal controls without history of cardiovascular disease as measured by magnetic resonance imaging: results from the KORA-FF4 Study.
    Cardiovasc Diabetol 2018 Jun 12;17(1):88. Epub 2018 Jun 12.
    Institute of Clinical Radiology, Ludwig-Maximilian-University Hospital, Munich, Germany.
    Objectives: Local, abdominal fat depots may be related to alterations in cardiac function and morphology due to a metabolic linkage. Thus, we aimed to determine their association with subtle cardiac changes and the potential interaction with hyperglycemic metabolic states.

    Methods: Subjects from the general population and without history of cardiovascular disease were drawn from the Cooperative Health Research in the Region of Augsburg FF4 cohort and underwent 3 T cardiac and body MRI. Read More

    Comparing the inflammatory profiles for incidence of diabetes mellitus and cardiovascular diseases: a prospective study exploring the 'common soil' hypothesis.
    Cardiovasc Diabetol 2018 Jun 12;17(1):87. Epub 2018 Jun 12.
    Department of Clinical Sciences, Lund University, CRC 60:13, Jan Waldenströms gata 35, 20502, Malmö, Sweden.
    Background: Chronic low-grade inflammation and associated insulin resistance and metabolic abnormalities have been proposed as 'common soil' for diabetes mellitus (DM) and cardiovascular disease (CVD). This paper aimed to investigate the inflammatory profiles of DM and CVD and to distinguish their shared and specific markers.

    Methods: Based on the Malmö Diet and Cancer cohort, total and differential leukocyte counts were measured in 25,969 participants without previous DM or CVD and were studied in relation to incident DM (mean follow-up 17. Read More

    Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials.
    Cardiovasc Diabetol 2018 Jun 12;17(1):85. Epub 2018 Jun 12.
    Department of Cardiovascular Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.
    Recent clinical trials investigating cardiovascular (CV) safety of newer antidiabetic agents have been rapidly and largely changing the landscape of diabetes care and providing highly important clinical information on decision-making regarding the choice of antidiabetic agents. Similar to the sodium-glucose cotransporter 2 (SGLT2) inhibitors, some glucagon-like peptide-1 receptor agonists (GLP-1RAs) have also demonstrated a marked risk reduction in major adverse CV events (MACE) in patients with type 2 diabetes at high risk of CV events. However, the two classes of agents differ largely in their pharmacological modes of action on glucose-lowering and CV parameters. Read More

    Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017.
    Cardiovasc Diabetol 2018 Jun 8;17(1):83. Epub 2018 Jun 8.
    Novo Nordisk A/S, Søborg, Denmark.
    Background: Cardiovascular disease (CVD) is a common comorbidity in type 2 diabetes (T2DM). CVD's prevalence has been growing over time.

    Purpose: To estimate the current prevalence of CVD among adults with T2DM by reviewing literature published within the last 10 years (2007-March 2017). Read More

    Skin autofluorescence predicts major adverse cardiovascular events in patients with type 1 diabetes: a 7-year follow-up study.
    Cardiovasc Diabetol 2018 Jun 8;17(1):82. Epub 2018 Jun 8.
    Nutrition Diabetology Unit, CHU Bordeaux, Haut-Levêque Hospital, Avenue Magellan, 33600, Pessac Cedex, France.
    Background: Advanced glycation end-products play a role in diabetic vascular complications. Their optical properties allow to estimate their accumulation in tissues by measuring the skin autofluorescence (SAF). We searched for an association between SAF and major adverse cardiovascular events (MACE) incidence in subjects with Type 1 Diabetes (T1D) during a 7 year follow-up. Read More

    Influence of micro- and macro-vascular disease and Tumor Necrosis Factor Receptor 1 on the level of lower-extremity amputation in patients with type 2 diabetes.
    Cardiovasc Diabetol 2018 Jun 8;17(1):81. Epub 2018 Jun 8.
    Centre d'Investigation Clinique CIC1402, INSERM, Université de Poitiers, CHU de Poitiers, Poitiers, France.
    Background: Patients with type 2 diabetes (T2D) face a high amputation rate. We investigated the relationship between the level of amputation and the presence of micro or macro-vascular disease and related circulating biomarkers, Tumor Necrosis Factor Receptor 1 (TNFR1) and Angiopoietin like-2 protein (ANGPTL2).

    Methods: We have analyzed data from 1468 T2D participants in a single center prospective cohort (the SURDIAGENE cohort). Read More

    Sex-specific associations between adolescent categories of BMI with cardiovascular and non-cardiovascular mortality in midlife.
    Cardiovasc Diabetol 2018 Jun 5;17(1):80. Epub 2018 Jun 5.
    The Israel Defense Forces Medical Corps, Tel Hashomer, Ramat Gan, Israel.
    Context: Most studies linking long-term consequences of adolescent underweight and obesity are limited to men.

    Objective: To assess the sex-specific association of adolescent BMI with cardiovascular- and non-cardiovascular-related mortality in young adulthood and midlife.

    Setting: A nationwide cohort. Read More

    Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: a comprehensive network meta-analysis of 166,371 participants from 170 randomized controlled trials.
    Cardiovasc Diabetol 2018 Jun 5;17(1):79. Epub 2018 Jun 5.
    Department of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China.
    Background: Cardiovascular (CV) safety of one anti-diabetic medication over another remains partially delineated. We sought to assess the comparative effect on CV outcomes among novel anti-diabetic agents.

    Methods: This study was registered with the International Prospective Register of Systematic Reviews (CRD 42016042063). Read More

    Influence of high density lipoprotein cholesterol levels on circulating monocytic angiogenic cells functions in individuals with type 2 diabetes mellitus.
    Cardiovasc Diabetol 2018 Jun 5;17(1):78. Epub 2018 Jun 5.
    Section of Diabetes and Metabolic Disease, Department of Clinical and Experimental Medicine, University of Pisa and Azienda Ospedaliero-Universitaria Pisana, Via Paradisa, 2, 56124, Pisa, Italy.
    Background: High-density lipoproteins (HDLs) can exert anti-atherogenic effects. On top of removing excess cholesterol through reverse cholesterol transport, HDLs play beneficial actions on endothelial function and integrity. In particular, HDLs are strong determinant of endothelial progenitor cells (EPCs) number and function. Read More

    Burden of cardiovascular risk factors and disease among patients with type 1 diabetes: results of the Australian National Diabetes Audit (ANDA).
    Cardiovasc Diabetol 2018 Jun 2;17(1):77. Epub 2018 Jun 2.
    School of Public Health and Preventive Medicine, Monash University, 5th Floor, The Alfred Centre, 99 Commercial Road, Melbourne, VIC, 3004, Australia.
    Background: Cardiovascular risk stratification is complex in type 1 diabetes. We hypothesised that traditional and diabetes-specific cardiovascular risk factors were prevalent and strongly associated with cardiovascular disease (CVD) among adults with type 1 diabetes attending Australian diabetes centres.

    Methods: De-identified, prospectively collected data from patients with type 1 diabetes aged ≥ 18 years in the 2015 Australian National Diabetes Audit were analysed. Read More

    Donor artery stenosis interactions with diastolic blood pressure on coronary collateral flow in type 2 diabetic patients with chronic total occlusion.
    Cardiovasc Diabetol 2018 Jun 1;17(1):76. Epub 2018 Jun 1.
    Department of Cardiology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui Jin Road II, Shanghai, 200025, People's Republic of China.
    Background: We investigated whether and to what extent stenosis of predominant collateral donor artery (PCDA) affects coronary collateral flow in relation to blood pressure (BP) in type 2 diabetic patients with chronic total occlusion (CTO).

    Methods: Collateral flow index (CFI) as derived from intracoronary pressure distal to occluded segment and mean aortic pressure in 220 type 2 diabetic patients and 220 propensity score matched non-diabetic controls undergoing percutaneous coronary intervention for CTO. The severity of PCDA stenosis was graded according to lumen diameter narrowing. Read More

    Circulating levels of adipose tissue-derived inflammatory factors in elderly diabetes patients with carotid atherosclerosis: a retrospective study.
    Cardiovasc Diabetol 2018 May 30;17(1):75. Epub 2018 May 30.
    Department of Endocrine, Capital Medical University, Xuanwu Hospital, Beijing, 100053, China.
    Background: Inflammation has been recognized as a key feature of both type 2 diabetes mellitus (T2DM) and atherosclerosis. However, the relationships between circulating levels of novel adipose tissue-derived inflammatory factors, including resistin, vaspin, and visfatin, and the severity of atherosclerosis have not been determined. Moreover, the associations between these inflammatory factors and obesity and insulin resistance in elderly patients remain to be clarified. Read More

    Exploration of the clinical benefits of sodium glucose co-transporter 2 inhibitors in diabetic patients with concomitant heart failure.
    Cardiovasc Diabetol 2018 May 25;17(1):74. Epub 2018 May 25.
    Department of Cardiovascular Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.
    Prevention and treatment strategies for heart failure (HF) in diabetes have not been fully established, at least partly due to lack of recognition of a pathological link between the two and effective antidiabetic agents for HF. Recent cardiovascular (CV) outcomes trials demonstrated that treatment with sodium glucose co-transporter 2 (SGLT2) inhibitors greatly improved major CV adverse events in type 2 diabetes (T2D) patients at high risk for CV events, seemingly driven by risk reduction in HF-related outcomes. The beneficial effects of SGLT2 inhibitors on such outcomes and the heart itself are unique characteristics among antidiabetic agents, and SGLT2 inhibitors are expected to be a promising therapeutic option for CV disease and HF care. Read More

    Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes.
    Cardiovasc Diabetol 2018 May 22;17(1):73. Epub 2018 May 22.
    Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine, 3-25-8, Nishi-Shinbashi, Minato-ku, Tokyo, 105-8461, Japan.
    Background: Type 2 diabetes mellitus (T2DM) greatly increases the risks of cardiovascular disease and heart failure. In particular, left ventricular diastolic dysfunction that develops from the early stages of T2DM is an important factor in the onset and exacerbation of heart failure. The effect of sodium-glucose cotransporter 2 inhibitors on left ventricular diastolic function has not been elucidated. Read More

    The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1α/CXCR4 pathway.
    Cardiovasc Diabetol 2018 May 19;17(1):60. Epub 2018 May 19.
    Department of Clinical Science and Education, Södersjukhuset, Internal Medicine, Karolinska Institutet, 118 83, Stockholm, Sweden.
    Background: Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) are approved drugs for the treatment of hyperglycemia in patients with type 2 diabetes. These effects are mainly mediated by inhibiting endogenous glucagon-like peptide-1 (GLP-1) cleavage. Interestingly, gliptins can also improve stroke outcome in rodents independently from GLP1. Read More

    No detectable differential microRNA expression between non-atherosclerotic arteries of type 2 diabetic patients (treated or untreated with metformin) and non-diabetic patients.
    Cardiovasc Diabetol 2018 May 17;17(1):72. Epub 2018 May 17.
    Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark.
    Background: Type 2 diabetes mellitus (T2DM) is an independent risk factor of cardiovascular disease (CVD), however, the underlying mechanisms are largely unknown. Using non-atherosclerotic internal thoracic arteries (ITAs) obtained from coronary artery bypass grafting, we previously identified a distinct elevation in the level of proteins comprising the arterial basement membrane in T2DM patients not treated with metformin. Altered transcription of genes encoding these proteins has not been observed, indicating alternative mechanisms of dysregulation. Read More

    Effects of linagliptin on endothelial function and postprandial lipids in coronary artery disease patients with early diabetes: a randomized, placebo-controlled, double-blind trial.
    Cardiovasc Diabetol 2018 May 17;17(1):71. Epub 2018 May 17.
    Cardiovascular Diabetology Research Group, Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria.
    Background: Early glucose lowering intervention in subjects with type 2 diabetes mellitus was demonstrated to be beneficial in terms of micro- and macrovascular risk reduction. However, most of currently ongoing cardiovascular outcome trials are performed in subjects with manifest atherosclerosis and long-standing diabetes. Therefore, the aim of this study is to investigate the effects of the dipeptidylpeptidase-4 inhibitor linagliptin in subjects with coronary artery disease (CAD) but early type 2 diabetes mellitus (T2DM) on a set of cardiovascular surrogate measurements. Read More

    Prevalence and incidence of complications at diagnosis of T2DM and during follow-up by BMI and ethnicity: a matched case-control analysis.
    Cardiovasc Diabetol 2018 May 15;17(1):70. Epub 2018 May 15.
    Melbourne EpiCentre, University of Melbourne and Melbourne Health, Melbourne, Australia.
    Aims: To estimate the risk of developing long-term major cardiovascular and renal complications in relation to levels of body mass index (BMI) in a population of White European (WE), African-Caribbean (AC), and South Asian (SA) patients with type 2 diabetes mellitus (T2DM).

    Materials And Methods: Patients with new diagnosis of T2DM, aged ≥ 18 years from January 2000 (n = 69,436) and their age-sex-ethnicity matched non-diabetic controls (n = 272,190) were identified from UK primary care database. Incidence rates ratios (IRRs) for non-fatal major cardiovascular events (MACE) and chronic kidney disease (CKD) in patients with T2DM compared to controls were estimated using multivariate Mantel-Cox model. Read More

    Childhood retinol-binding protein 4 (RBP4) levels predicting the 10-year risk of insulin resistance and metabolic syndrome: the BCAMS study.
    Cardiovasc Diabetol 2018 May 14;17(1):69. Epub 2018 May 14.
    Department of Endocrinology/Diabetes, The Children's Hospital of Philadelphia, Perelman School of Medicine at University of Pennsylvania, Philadelphia, PA, 19104, USA.
    Background: Elevated retinol-binding protein 4 (RBP4) levels may contribute to the development of metabolic abnormalities, but prospective studies evaluating the association between childhood RBP4 levels and metabolic syndrome (MS) in adulthood are lacking. We investigated whether RBP4 levels during childhood predict cardiometabolic risk at 10-year follow-up.

    Methods: The relationships between RBP4 levels, the established adipokines (leptin and adiponectin) and the components of MS were examined in 3445 school-aged children recruited in 2004 for the Beijing Child and Adolescent Metabolic Syndrome study. Read More

    Adverse effects of Hif1a mutation and maternal diabetes on the offspring heart.
    Cardiovasc Diabetol 2018 May 12;17(1):68. Epub 2018 May 12.
    Laboratory of Molecular Pathogenetics, Institute of Biotechnology CAS, BIOCEV, Center of Excellence, Prumyslova 595, 25250, Vestec, Czechia.
    Background: Epidemiological studies show that maternal diabetes predisposes offspring to cardiovascular and metabolic disorders. However, the precise mechanisms for the underlying penetrance and disease predisposition remain poorly understood. We examined whether hypoxia-inducible factor 1 alpha, in combination with exposure to a diabetic intrauterine environment, influences the function and molecular structure of the adult offspring heart. Read More

    Associations of coronary artery calcified plaque density with mortality in type 2 diabetes: the Diabetes Heart Study.
    Cardiovasc Diabetol 2018 May 11;17(1):67. Epub 2018 May 11.
    Center for Diabetes Research, Wake Forest School of Medicine, Winston-Salem, NC, USA.
    Background: Coronary artery calcified plaque (CAC) is strongly predictive of cardiovascular disease (CVD) events and mortality, both in general populations and individuals with type 2 diabetes at high risk for CVD. CAC is typically reported as an Agatston score, which is weighted for increased plaque density. However, the role of CAC density in CVD risk prediction, independently and with CAC volume, remains unclear. Read More

    Diabetic retinopathy is associated with the presence and burden of subclinical carotid atherosclerosis in type 1 diabetes.
    Cardiovasc Diabetol 2018 May 4;17(1):66. Epub 2018 May 4.
    Department of Endocrinology and Nutrition, University Hospital and Health Science Research Institute Germans Trias i Pujol, Carretera Canyet S/N, 08916, Badalona, Spain.
    Background: Cardiovascular (CV) disease due to atherosclerosis is a major cause of morbidity and mortality in adult patients with diabetes, either type 1 or type 2 diabetes. The aim of the study was to assess the association of the frequency and the burden of subclinical carotid atherosclerotic disease in patients with type 1 diabetes according to the presence and severity of diabetic retinopathy (DR).

    Methods: A cross-sectional study was conducted in 340 patients with type 1 diabetes (41. Read More

    The synergistic effects of saxagliptin and metformin on CD34+ endothelial progenitor cells in early type 2 diabetes patients: a randomized clinical trial.
    Cardiovasc Diabetol 2018 May 3;17(1):65. Epub 2018 May 3.
    The GW Medical Faculty Associates, Washington, DC, USA.
    Aims: Type 2 diabetes is associated with endothelial dysfunction leading to cardiovascular disease. CD34+ endothelial Progenitor Cells (EPCs) are responsible for endothelial repair and neo-angiogenesis and can be used as a cardiovascular disease risk biomarker. This study investigated whether the addition of saxagliptin, a DPP-IV inhibitor, to metformin, may reduce cardiovascular disease risk in addition to improving glycemic control in Type 2 diabetes patients. Read More

    Exercise training and endothelial function in patients with type 2 diabetes: a meta-analysis.
    Cardiovasc Diabetol 2018 May 2;17(1):64. Epub 2018 May 2.
    Division of Sports and Rehabilitation Medicine, Ulm University Medical Center, Ulm, Germany.
    Background And Aims: Exercise training is considered a cornerstone in the management of type 2 diabetes, which is associated with impaired endothelial function. However, the association of exercise training with endothelial function in type 2 diabetes patients has not been fully understood. This meta-analysis aimed to investigate their associations with focus on exercise types. Read More

    Cardiovascular disease risk factor responses to a type 2 diabetes care model including nutritional ketosis induced by sustained carbohydrate restriction at 1 year: an open label, non-randomized, controlled study.
    Cardiovasc Diabetol 2018 May 1;17(1):56. Epub 2018 May 1.
    Virta Health, San Francisco, CA, USA.
    Background: Cardiovascular disease (CVD) is a leading cause of death among adults with type 2 diabetes mellitus (T2D). We recently reported that glycemic control in patients with T2D can be significantly improved through a continuous care intervention (CCI) including nutritional ketosis. The purpose of this study was to examine CVD risk factors in this cohort. Read More

    Prognostic value of the Stanniocalcin-2/PAPP-A/IGFBP-4 axis in ST-segment elevation myocardial infarction.
    Cardiovasc Diabetol 2018 Apr 30;17(1):63. Epub 2018 Apr 30.
    Heart Institute, Hospital Universitari Germans Trias i Pujol, Carretera de Canyet s/n, Badalona, 08916, Barcelona, Spain.
    Objective: The aim of the present study was to evaluate the prognostic value of the Stanniocalcin-2/PAPP-A/IGFBP-4 axis in patients with ST-segment elevation myocardial infarction (STEMI).

    Methods: Observational cohort study performed in 1085 consecutive STEMI patients treated with early reperfusion between February 2011 and August 2014. Stanniocalcin-2, PAPP-A, and IGFBP-4 were measured using state-of-the art immunoassays. Read More

    SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice.
    Cardiovasc Diabetol 2018 Apr 27;17(1):62. Epub 2018 Apr 27.
    Department of Food Science and Human Nutrition, Colorado State University, Fort Collins, CO, 80523, USA.
    Background: Type 2 diabetes (T2D) is associated with generalized vascular dysfunction characterized by increases in large artery stiffness, endothelial dysfunction, and vascular smooth muscle dysfunction. Sodium glucose cotransporter 2 inhibitors (SGLT2i) represent the most recently approved class of oral medications for the treatment of T2D, and have been shown to reduce cardiovascular and overall mortality. Although it is currently unclear how SGLT2i decrease cardiovascular risk, an improvement in vascular function is one potential mechanism. Read More

    Novel risk genes identified in a genome-wide association study for coronary artery disease in patients with type 1 diabetes.
    Cardiovasc Diabetol 2018 Apr 25;17(1):61. Epub 2018 Apr 25.
    UFR de Médecine et Pharmacie, Université de Poitiers, Poitiers, France.
    Background: Patients with type 1 diabetes are more at risk of coronary artery disease than the general population. Although evidence points to a genetic risk there have been no study investigating genetic risk factors of coronary artery disease specific to individuals with type 1 diabetes. To identify low frequency and common genetic variations associated with coronary artery disease in populations of individuals with type 1 diabetes. Read More

    Prevalence of left ventricular systolic dysfunction and heart failure with reduced ejection fraction in men and women with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Cardiovasc Diabetol 2018 Apr 18;17(1):58. Epub 2018 Apr 18.
    Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht University, PO Box 85500, 3508 AB, Utrecht, The Netherlands.
    Background: Type 2 diabetes mellitus (T2D) is associated with the development of left ventricular systolic dysfunction (LVSD) and heart failure with reduced ejection fraction (HFrEF). T2D patients with LVSD are at higher risk of mortality and morbidity than patients without LVSD, while progression of LVSD can be delayed or halted by the use of proven therapies. As estimates of the prevalence are scarce and vary considerably, the aim of this study was to retrieve summary estimates of the prevalence of LVSD/HFrEF in T2D and to see if there were any sex differences. Read More

    The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin.
    Cardiovasc Diabetol 2018 Apr 18;17(1):59. Epub 2018 Apr 18.
    Diabetes and Cardiovascular Center, University of Missouri School of Medicine, Columbia, MO, USA.
    Multiple population based analyses have demonstrated a high incidence of cardiovascular disease (CVD) and cardiovascular (CV) mortality in subjects with T2DM that reduces life expectancy by as much as 15 years. Importantly, the CV system is particularly sensitive to the metabolic and immune derangements present in obese pre-diabetic and diabetic individuals; consequently, CV dysfunction is often the initial CV derangement to occur and promotes the progression to end organ/tissue damage in T2DM. Specifically, diabetic CVD can manifest as microvascular complications, such as nephropathy, retinopathy, and neuropathy, as well as, macrovascular impairments, including ischemic heart disease, peripheral vascular disease, and cerebrovascular disease. Read More

    Diabetes, cardiovascular disease and the microcirculation.
    Cardiovasc Diabetol 2018 Apr 18;17(1):57. Epub 2018 Apr 18.
    Novartis Pharma AG, Basel, Switzerland.
    Cardiovascular disease (CVD) is the leading cause of mortality in people with type 2 diabetes mellitus (T2DM), yet a significant proportion of the disease burden cannot be accounted for by conventional cardiovascular risk factors. Hypertension occurs in majority of people with T2DM, which is substantially more frequent than would be anticipated based on general population samples. The impact of hypertension is considerably higher in people with diabetes than it is in the general population, suggesting either an increased sensitivity to its effect or a confounding underlying aetiopathogenic mechanism of hypertension associated with CVD within diabetes. Read More

    Antidiabetic treatment patterns and specialty care utilization among patients with type 2 diabetes and cardiovascular disease.
    Cardiovasc Diabetol 2018 Apr 10;17(1):54. Epub 2018 Apr 10.
    Department of Endocrinology, Endocrinology and Metabolism Institute, Cleveland Clinic, 9500 Euclid Avenue, Desk F-20, Cleveland, OH, USA.
    Background: To evaluate real-world patient characteristics, medication use, and health care utilization patterns in patients with type 2 diabetes with established cardiovascular disease (CVD).

    Methods: Cross-sectional analysis of patients with type 2 diabetes seen at Cleveland Clinic from 2005 to 2016, divided into two cohorts: with-CVD and without-CVD. Patient demographics and antidiabetic medications were recorded in December 2016; department encounters included all visits from 1/1/2016 to 12/31/2016. Read More

    Liraglutide suppresses non-esterified free fatty acids and soluble vascular cell adhesion molecule-1 compared with metformin in patients with recent-onset type 2 diabetes.
    Cardiovasc Diabetol 2018 Apr 10;17(1):53. Epub 2018 Apr 10.
    Department of Endocrinology and Metabolism, Zhongshan Hospital Xiamen University, 201-209 Hubin South Road, Xiamen, 361004, People's Republic of China.
    Background: It has been suggested that liraglutide could have an impact on glucose and lipid metabolism disorder and adhesion molecule activation, which may play important roles in the vascular damage of diabetes. In this study, we examined the effects of liraglutide versus metformin on non-esterified free fatty acids, beta-cell insulin secretion, and adhesion molecule levels in patients with recent-onset type 2 diabetes mellitus.

    Methods: In this study, 60 patients newly diagnosed with type 2 diabetes mellitus (mean age 33. Read More

    Sarcopenic obesity assessed using dual energy X-ray absorptiometry (DXA) can predict cardiovascular disease in patients with type 2 diabetes: a retrospective observational study.
    Cardiovasc Diabetol 2018 Apr 10;17(1):55. Epub 2018 Apr 10.
    Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
    Background: Sarcopenic obesity, defined as reduced skeletal muscle mass and power with increased adiposity, was reported to be associated with cardiovascular disease risks in previous cross-sectional studies. Whole body dual-energy X-ray absorptiometry (DXA) can simultaneously evaluate both fat and muscle mass, therefore, whole body DXA may be suitable for the diagnosis of sarcopenic obesity. However, little is known regarding whether sarcopenic obesity determined using whole body DXA could predict incident cardiovascular disease (CVD). Read More

    Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy.
    Cardiovasc Diabetol 2018 Apr 9;17(1):52. Epub 2018 Apr 9.
    Department of Experimental and Clinical Medicine, Magna Græcia University, Viale Europa, 88100, Catanzaro, Italy.
    Background: Cardiovascular protection following empagliflozin therapy is not entirely attributable to the glucose lowering effect. Increased hematocrit might influence the shear stress that is the main force acting on the endothelium, regulating its anti-atherogenic function.

    Objective: We designed the study with the aim of investigating the effect of empagliflozin on blood viscosity and shear stress in the carotid arteries. Read More

    The effect of change in fasting glucose on the risk of myocardial infarction, stroke, and all-cause mortality: a nationwide cohort study.
    Cardiovasc Diabetol 2018 Apr 7;17(1):51. Epub 2018 Apr 7.
    Clinical Medical Sciences, College of Medicine, Seoul National University, Seoul, South Korea.
    Background: The effect of change in blood glucose levels on the risk of cardiovascular disease among individuals without diabetes is currently unclear. We aimed to examine the association of change in fasting serum glucose with incident cardiovascular disease and all-cause mortality among representative large population.

    Methods: We analyzed the data from retrospective cohort of Korean National Health Insurance Service. Read More

    Urinary proteomics for prediction of mortality in patients with type 2 diabetes and microalbuminuria.
    Cardiovasc Diabetol 2018 Apr 6;17(1):50. Epub 2018 Apr 6.
    Institute of Cardiovascular and Medical Sciences, University of Glasgow, 126 University Place, Glasgow, G12 8TA, UK.
    Background: The urinary proteomic classifier CKD273 has shown promise for prediction of progressive diabetic nephropathy (DN). Whether it is also a determinant of mortality and cardiovascular disease in patients with microalbuminuria (MA) is unknown.

    Methods: Urine samples were obtained from 155 patients with type 2 diabetes and confirmed microalbuminuria. Read More

    Correction to: Type 2 diabetes-associated carotid plaque burden is increased in patients with retinopathy compared to those without retinopathy.
    Cardiovasc Diabetol 2018 Apr 5;17(1):49. Epub 2018 Apr 5.
    Department of Endocrinology and Nutrition, Health Sciences Research Institute and University Hospital Germans Trias i Pujol, Badalona, Spain.
    The author found errors in Table 1 after publication of the original article [1]. Read More

    Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism.
    Cardiovasc Diabetol 2018 Apr 4;17(1):48. Epub 2018 Apr 4.
    Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, BeiLiShi Road 167, Beijing, 100037, China.
    Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9), a major regulator of cholesterol homeostasis, is associated with glucose metabolism. Liraglutide, a glucagon-like peptide-1 receptor agonist, can increase insulin secretion in a glucose-dependent manner and lower blood glucose. We aimed to investigate the relationship between liraglutide and PCSK9. Read More

    The role of obesity in carotid plaque instability: interaction with age, gender, and cardiovascular risk factors.
    Cardiovasc Diabetol 2018 Mar 29;17(1):46. Epub 2018 Mar 29.
    Anatomic Pathology, Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata", Via Montpellier 1, 00133, Rome, Italy.
    Background: In the last decade, several studies have reported an unexpected and seemingly paradoxical inverse correlation between BMI and incidence of cardiovascular diseases. This so called "obesity paradox effect" has been mainly investigated through imaging methods instead of histologic evaluation, which is still the best method to study the instability of carotid plaque. Therefore, the purpose of our study was to evaluate by histology the role of obesity in destabilization of carotid plaques and the interaction with age, gender and other major cerebrovascular risk factors. Read More

    HbA1c variability and diabetic peripheral neuropathy in type 2 diabetic patients.
    Cardiovasc Diabetol 2018 Mar 29;17(1):47. Epub 2018 Mar 29.
    Department of Endocrinology, The Second Affiliated Hospital of Nantong University and First People's Hospital of Nantong City, No. 6, Haierxiang North Road, Nantong, 226001, China.
    Background: Diabetic complications may be associated with impaired time-dependent glycemic control. Therefore, long-term glycemic variability, assessed by variations in haemoglobin A1c (HbA1c), may be a potential risk factor for microvascular complications, such as diabetic peripheral neuropathy (DPN). We investigated the association of HbA1c variability with DPN in patients with type 2 diabetes. Read More

    Exercise capacity in diabetes mellitus is predicted by activity status and cardiac size rather than cardiac function: a case control study.
    Cardiovasc Diabetol 2018 Mar 23;17(1):44. Epub 2018 Mar 23.
    Department of Cardiology, St Vincent's Hospital Melbourne, Fitzroy, Australia.
    Background: The reasons for reduced exercise capacity in diabetes mellitus (DM) remains incompletely understood, although diastolic dysfunction and diabetic cardiomyopathy are often favored explanations. However, there is a paucity of literature detailing cardiac function and reserve during incremental exercise to evaluate its significance and contribution. We sought to determine associations between comprehensive measures of cardiac function during exercise and maximal oxygen consumption ([Formula: see text]peak), with the hypothesis that the reduction in exercise capacity and cardiac function would be associated with co-morbidities and sedentary behavior rather than diabetes itself. Read More

    Bone markers and cardiovascular risk in type 2 diabetes patients.
    Cardiovasc Diabetol 2018 Mar 23;17(1):45. Epub 2018 Mar 23.
    Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, PO box 85500, 3508 GA, Utrecht, The Netherlands.
    Background: Vascular calcifications are associated with a three- to fourfold increased risk of cardiovascular disease (CVD) and are highly prevalent in type 2 diabetes patients. Emerging evidence indicates that vascular calcification is a process of active bone formation regulated by stimulators and inhibitors of calcification. Therefore, this study aimed to evaluate whether six bone markers are associated with CVD risk in patients with type 2 diabetes. Read More

    Molecular mechanism of diabetic cardiomyopathy and modulation of microRNA function by synthetic oligonucleotides.
    Cardiovasc Diabetol 2018 Mar 22;17(1):43. Epub 2018 Mar 22.
    Department of Physiology-HeartOtago, University of Otago, 270, Great King Street, Dunedin, 9010, New Zealand.
    Diabetic cardiomyopathy (DCM) is a chronic complication in individuals with diabetes and is characterized by ventricular dilation and hypertrophy, diastolic dysfunction, decreased or preserved systolic function and reduced ejection fraction eventually resulting in heart failure. Despite being well characterized, the fundamental mechanisms leading to DCM are still elusive. Recent studies identified the involvement of small non-coding small RNA molecules such as microRNAs (miRs) playing a key role in the etiology of DCM. Read More

    Correction to: HbA versus oral glucose tolerance test as a method to diagnose diabetes mellitus in vascular surgery patients.
    Cardiovasc Diabetol 2018 Mar 22;17(1):42. Epub 2018 Mar 22.
    Department of Clinical Sciences, University of Bergen, Bergen, Norway.
    The authors found errors in Table 1 after publication of the original article [1].The correct values for medical history of coronary artery disease (CAD) at baseline are 110 (40%) of all patients, 54 (35.5%) of patients categorized as having normoglycaemia, 42 (46. Read More

    Association between triglyceride glucose index and arterial stiffness in Korean adults.
    Cardiovasc Diabetol 2018 Mar 21;17(1):41. Epub 2018 Mar 21.
    Division of Endocrinology, Department of Internal Medicine, Yonsei University College of Medicine, Gangnam Severance Hospital, 211, Eonju-ro, Gangnam-gu, Seoul, South Korea.
    Background: The triglyceride glucose (TyG) index has been suggested as a simple surrogate marker of insulin resistance. However, there are limited data regarding the association between the TyG index and arterial stiffness in adults. Therefore, we evaluated the relationship between the TyG index and arterial stiffness as measured based on brachial ankle pulse wave velocity (baPWV) in Korean adults. Read More

    Relationships between epicardial adipose tissue thickness and adipo-fibrokine indicator profiles post-myocardial infarction.
    Cardiovasc Diabetol 2018 Mar 16;17(1):40. Epub 2018 Mar 16.
    Federal State Budgetary Institution, Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia.
    Background: Determination of the impact of visceral obesity and epicardial adipose tissue thickness on stimulating growth factor levels during hospitalization for myocardial infarction is of potential importance for predicting outcomes and assessing the development of cardiofibrotic changes associated with maladaptive myocardial remodeling. In this study, we aimed to investigate the relationships between epicardial adipose tissue thickness, adipokine profiles, and the stimulating growth factor 2/interleukin-33 signaling system during hospitalization for myocardial infarction, and with the cardiac fibrosis extent 1-year post-MI in patients with visceral obesity.

    Methods: Eighty-eight patients with myocardial infarction were grouped based on their visceral obesity. Read More

    1 OF 30